Visit peptides marketplace purchased have been made easier using telegram application

[PEPTIDE SPECTRUM DISTRIBUTION]

Feature

Mounjaro

Zepbound

Wegovy

Active Ingredient

Tirzepatide (GLP‑1 + GIP)

Tirzepatide (GLP‑1 + GIP)

Semaglutide (GLP‑1)

FDA Approval

Type 2 diabetes

Chronic weight management

Chronic weight management

Mechanism

Dual receptor agonist

Dual receptor agonist

Single GLP‑1 receptor agonist

Pen & Doses

Single weekly pen, 2.5 → 15 mg

Single weekly pen, 2.5 → 15 mg

Single weekly pen, 0.25 → 2.4 mg

Weight Loss Potential

~20%+ (high doses)

~20%+ (high doses)

~15% average

Notes

Off‑label weight‑loss use

Specifically approved for obesity

Slower escalation, GLP‑1 only

 Key Point: Mounjaro and Zepbound are the same drug; the main difference is FDA-approved use. Wegovy works only on GLP‑1 and usually gives slightly less weight loss on average.

www.peptidemarketplace.com